HL-60/MX1細(xì)胞
器官來源： 外周血
ATCC Number： CRL-2258?
相關(guān)**： 其他**
年限： 36 years
數(shù)量： 大量
生長狀態(tài)： 懸浮生長
運輸方式： 凍存運輸
細(xì)胞形態(tài)： **樣
是否是腫瘤細(xì)胞： 0
物種來源： 人
Designations: HL-60/MX1
Depositors: WG Harker
HL-60/MX1細(xì)胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Homo sapiens
Morphology: lymphoblast
Source: Organ: peripheral blood
Disease: acute promyelocytic leukemia
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
DNA Profile (STR): Amelogenin: X
CSF1PO: 13,14
D13S317: 8,11
D16S539: 11
D5S818: 12
D7S820: 11,12
THO1: 7,8
TPOX: 8
vWA: 16
Age: 36 years
Gender: female
HL-60/MX1細(xì)胞Ethnicity: Caucasian
Comments: HL-60/MX1 is a mitoxantrone resistant derivative of the HL-60 cell line (see ATCC CCL-240) which was obtained from peripheral blood leukocytes obtained by leukopheresis from patient with acute promyelocytic leukemia.
The cells were selected and subcloned in 1987 for resistance to 39 nM mitoxantrone, an anthracenedione antitumor agent.
Subsequent exposure of the HL-60/MX1 cells to higher concentrations of mitoxantrone led to the emergence of cells capable of growth at 190 nM (see ATCC CRL-2257, HL-60/MX2).
HL-60/MX1 cells display atypical multidrug resistance (MDR), altered topoisomerase II catalytic activity and reduced levels of topoisomerase II alpha and beta proteins.
HL-60/MX1 cells are cross resistant to etoposide, teniposide, bisantrene.
Dactinomycin, 4'-(9-acridinylamino)methane-sulfon-m-anisidide, HL-60/MX1細(xì)胞and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloids vincristine and vinblastine, melphalan, mitomycin C and cisplatin.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of medium. Start new cultures at 2 X 10 exp5 viable cells/ml and subculture at 1 X 10 exp6 cells/ml.
References: HL-60/MX1細(xì)胞23073: Harker WG, et al. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49: 4542-4549, 1989. PubMed: 2568172
